Linked Data API

Show Search Form

Search Results

422970
star this property registered interest false more like this
star this property date less than 2015-10-21more like thismore than 2015-10-21
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading General Practitioners: Databases more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, pursuant to the Answer of 23 July 2015 to Question 7630, how many GP practices in each pathfinder area have signed up to care.data to date in total. more like this
star this property tabling member constituency Copeland more like this
star this property tabling member printed
Mr Jamie Reed more like this
star this property uin 12767 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-10-29more like thismore than 2015-10-29
star this property answer text <br /> <br /><p>The information requested is provided in the following table:</p><p><strong></strong></p><table><tbody><tr><td><p>Pathfinder clinical commissioning groups.</p></td><td><p>GP Practices</p></td></tr><tr><td><p>Blackburn with Darwen</p></td><td><p>23</p></td></tr><tr><td><p>Leeds</p></td><td><p>15</p></td></tr><tr><td><p>West Hampshire</p></td><td><p>30</p></td></tr><tr><td><p>Somerset</p></td><td><p>56</p></td></tr></tbody></table><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2015-10-29T17:11:25.373Zmore like thismore than 2015-10-29T17:11:25.373Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
1503
unstar this property label Biography information for Mr Jamie Reed more like this
422655
star this property registered interest false more like this
star this property date less than 2015-10-20more like thismore than 2015-10-20
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading NHS England more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, if he will place in the Library an explanation of the organisational structure, including current post-holders, of the senior management of NHS England. more like this
star this property tabling member constituency Washington and Sunderland West more like this
star this property tabling member printed
Mrs Sharon Hodgson more like this
star this property uin 12514 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-10-28more like thismore than 2015-10-28
star this property answer text <br /><p>An organogram and explanation of the roles of the chief executive and the seven national directors of NHS England is attached.</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2015-10-28T17:21:24.177Zmore like thismore than 2015-10-28T17:21:24.177Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
unstar this property attachment
1
star this property file name NHS England National Directors - Structure Chart.pdf more like this
star this property title NHS England Structure Chart- National Directors more like this
star this property tabling member
1521
unstar this property label Biography information for Mrs Sharon Hodgson more like this
423580
star this property registered interest false more like this
star this property date less than 2015-10-23more like thismore than 2015-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Lymphoedema: Health Services more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, if he will issue a response to the report by the National Cancer Action Team, Lymphoedema Services in England: A Case for Change, published in March 2013; and if he will make a statement. more like this
star this property tabling member constituency Hampstead and Kilburn more like this
star this property tabling member printed
Tulip Siddiq more like this
star this property uin 13149 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-11-02more like thismore than 2015-11-02
star this property answer text <br /><p>At its meeting on 15 October 2015, the Prescribed Specialist Services Advisory Group (PSSAG) considered a proposal from the British Lymphology Society for a service for lymphoedema to be nationally commissioned. PSSAG’s recommendations on all proposals considered at this meeting will be put to Ministers shortly.</p><br /><p>It is for Ministers to decide which services should be prescribed as specialised services and therefore nationally commissioned by NHS England. Ministers make these decisions based on advice from PSSAG.</p><br /><p>Regarding the <em>Lymphoedema Services in England: A Case for Change</em> report, published by the National Cancer Action Team in March 2013, the main recommendation for the NHS Commissioning Board (now NHS England) to consider was the creation of a lymphoedema strategy for England.</p><br /><p>NHS England is focused on a system-wide approach that aims to ensure improvements in outcomes for all individuals with long-term conditions, including lymphoedema, rather than focusing on individual strategies for specific conditions.</p><br /><p>The commissioning of services for the treatment and care of lymphoedema patients is a local matter, and information concerning the arrangement of such services is not collected. People with lymphoedema can usually be managed through routine access to primary or second care services and there is range of guidance to support local commissioning, including: an international consensus document on best practice in the diagnosis, treatment care and support of people with; and National Institute for Health and Care Excellence guidance on advanced breast cancer, which provides advice on lymphoedema care. Both sets of guidance can be found at the following links:</p><br /><p><a href="http://www.woundsinternational.com/media/issues/210/files/content_175.pdf" target="_blank">www.woundsinternational.com/media/issues/210/files/content_175.pdf</a></p><br /><p><a href="http://www.nice.org.uk/guidance/cg81/resources/advanced-breast-cancer-diagnosis-and-treatment-975683850181" target="_blank">www.nice.org.uk/guidance/cg81/resources/advanced-breast-cancer-diagnosis-and-treatment-975683850181</a></p><p><strong></strong></p><br />
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
13148 more like this
13150 more like this
star this property question first answered
less than 2015-11-02T17:47:43.257Zmore like thismore than 2015-11-02T17:47:43.257Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
4518
unstar this property label Biography information for Tulip Siddiq more like this
423582
star this property registered interest false more like this
star this property date less than 2015-10-23more like thismore than 2015-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Lymphoedema: Health Services more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what progress the Prescribed Specialist Services Advisory Group has made on discussions on proposals for a nationally-commissioned specialist lymphology service. more like this
star this property tabling member constituency Hampstead and Kilburn more like this
star this property tabling member printed
Tulip Siddiq more like this
star this property uin 13148 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-11-02more like thismore than 2015-11-02
star this property answer text <br /><p>At its meeting on 15 October 2015, the Prescribed Specialist Services Advisory Group (PSSAG) considered a proposal from the British Lymphology Society for a service for lymphoedema to be nationally commissioned. PSSAG’s recommendations on all proposals considered at this meeting will be put to Ministers shortly.</p><br /><p>It is for Ministers to decide which services should be prescribed as specialised services and therefore nationally commissioned by NHS England. Ministers make these decisions based on advice from PSSAG.</p><br /><p>Regarding the <em>Lymphoedema Services in England: A Case for Change</em> report, published by the National Cancer Action Team in March 2013, the main recommendation for the NHS Commissioning Board (now NHS England) to consider was the creation of a lymphoedema strategy for England.</p><br /><p>NHS England is focused on a system-wide approach that aims to ensure improvements in outcomes for all individuals with long-term conditions, including lymphoedema, rather than focusing on individual strategies for specific conditions.</p><br /><p>The commissioning of services for the treatment and care of lymphoedema patients is a local matter, and information concerning the arrangement of such services is not collected. People with lymphoedema can usually be managed through routine access to primary or second care services and there is range of guidance to support local commissioning, including: an international consensus document on best practice in the diagnosis, treatment care and support of people with; and National Institute for Health and Care Excellence guidance on advanced breast cancer, which provides advice on lymphoedema care. Both sets of guidance can be found at the following links:</p><br /><p><a href="http://www.woundsinternational.com/media/issues/210/files/content_175.pdf" target="_blank">www.woundsinternational.com/media/issues/210/files/content_175.pdf</a></p><br /><p><a href="http://www.nice.org.uk/guidance/cg81/resources/advanced-breast-cancer-diagnosis-and-treatment-975683850181" target="_blank">www.nice.org.uk/guidance/cg81/resources/advanced-breast-cancer-diagnosis-and-treatment-975683850181</a></p><p><strong></strong></p><br />
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
13149 more like this
13150 more like this
star this property question first answered
less than 2015-11-02T17:47:43.193Zmore like thismore than 2015-11-02T17:47:43.193Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
4518
unstar this property label Biography information for Tulip Siddiq more like this
423584
star this property registered interest false more like this
star this property date less than 2015-10-23more like thismore than 2015-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Lymphoedema: Health Services more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what proportion of Clinical Commissioning Groups (CCGs) commission services are for the treatment and care of lymphoedema patients; and what guidance has been issued to CCGs on the commissioning of those services. more like this
star this property tabling member constituency Hampstead and Kilburn more like this
star this property tabling member printed
Tulip Siddiq more like this
star this property uin 13150 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-11-02more like thismore than 2015-11-02
star this property answer text <br /><p>At its meeting on 15 October 2015, the Prescribed Specialist Services Advisory Group (PSSAG) considered a proposal from the British Lymphology Society for a service for lymphoedema to be nationally commissioned. PSSAG’s recommendations on all proposals considered at this meeting will be put to Ministers shortly.</p><br /><p>It is for Ministers to decide which services should be prescribed as specialised services and therefore nationally commissioned by NHS England. Ministers make these decisions based on advice from PSSAG.</p><br /><p>Regarding the <em>Lymphoedema Services in England: A Case for Change</em> report, published by the National Cancer Action Team in March 2013, the main recommendation for the NHS Commissioning Board (now NHS England) to consider was the creation of a lymphoedema strategy for England.</p><br /><p>NHS England is focused on a system-wide approach that aims to ensure improvements in outcomes for all individuals with long-term conditions, including lymphoedema, rather than focusing on individual strategies for specific conditions.</p><br /><p>The commissioning of services for the treatment and care of lymphoedema patients is a local matter, and information concerning the arrangement of such services is not collected. People with lymphoedema can usually be managed through routine access to primary or second care services and there is range of guidance to support local commissioning, including: an international consensus document on best practice in the diagnosis, treatment care and support of people with; and National Institute for Health and Care Excellence guidance on advanced breast cancer, which provides advice on lymphoedema care. Both sets of guidance can be found at the following links:</p><br /><p><a href="http://www.woundsinternational.com/media/issues/210/files/content_175.pdf" target="_blank">www.woundsinternational.com/media/issues/210/files/content_175.pdf</a></p><br /><p><a href="http://www.nice.org.uk/guidance/cg81/resources/advanced-breast-cancer-diagnosis-and-treatment-975683850181" target="_blank">www.nice.org.uk/guidance/cg81/resources/advanced-breast-cancer-diagnosis-and-treatment-975683850181</a></p><p><strong></strong></p><br />
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
13148 more like this
13149 more like this
star this property question first answered
less than 2015-11-02T17:47:43.333Zmore like thismore than 2015-11-02T17:47:43.333Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
4518
unstar this property label Biography information for Tulip Siddiq more like this
434002
star this property registered interest false more like this
star this property date less than 2015-12-03more like thismore than 2015-12-03
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Obesity: Surgery more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, whether it is his policy that clinical commissioning groups (CCGs) will be required to meet current national service standards for the provision of obesity surgery after the planned transfer of obesity surgery commissioning responsibilities from NHS England to CCGs in April 2016. more like this
star this property tabling member constituency Easington more like this
star this property tabling member printed
Grahame Morris more like this
star this property uin 18622 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-12-10more like thismore than 2015-12-10
star this property answer text <br /><p>CCGs will have the full commissioning responsibility for the obesity services within their remit to set standards for services for their population and to make clinical commissioning policy decisions in terms of patient eligibility with effect from April 2016.</p><br /><p>NHS England is supporting the transfer of commissioning responsibilities to CCGs by providing clinical guidance on standards for the adult obesity surgery pathway. This guidance is in development, supported by national clinical experts.</p><br /><p>The draft clinical commissioning policy includes reference to the relevant National Institute for Health and Care Excellence guidance to support CCGs in determining patient eligibility to obesity surgery. The draft service specification will reflect best practice and describes the standard providers will need to meet for the surgical service.</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2015-12-10T14:18:24.76Zmore like thismore than 2015-12-10T14:18:24.76Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
3973
unstar this property label Biography information for Grahame Morris more like this
437917
star this property registered interest false more like this
star this property date less than 2015-12-14more like thismore than 2015-12-14
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Pharmaceutical Price Regulation Scheme more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, which companies have left the voluntary pharmaceutical price regulation scheme in each month since January 2014 to date; and if he will make a statement. more like this
star this property tabling member constituency Aberavon more like this
star this property tabling member printed
Stephen Kinnock more like this
star this property uin 19894 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-12-17more like thismore than 2015-12-17
star this property answer text <br /><p>Five companies have left the Pharmaceutical Price Regulation Scheme since January 2014 as follows:</p><br /><p>- Derma November 2014;</p><p>- Genus (Thornton &amp; Ross) November 2014;</p><p>- Vifor May 2015;</p><p>- Baxter October 2015; and</p><p>- Martindale October 2015</p><br /><p>The Department estimates the financial effect to be a loss of around £10 million in 2015/16.</p><br /><p>The Department’s consultation on options to amend the statutory scheme to control prices of branded health service medicines closed on 4 December 2015. The consultation was accompanied by an Impact Assessment which can be accessed:</p><br /><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf</a></p><br /><p>The Department’s analysis in the Impact Assessment concludes that the options would reduce National Health Service spending on drugs without affecting the use of those drugs in the NHS. The consultation sought views, comments and evidence on the potential impacts and operation of the options to revise thestatutory branded prices scheme. The Department is considering the responses received and will respond to the consultation in early 2016.</p><br />
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
19895 more like this
19897 more like this
star this property question first answered
less than 2015-12-17T16:19:37.057Zmore like thismore than 2015-12-17T16:19:37.057Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
4359
unstar this property label Biography information for Stephen Kinnock more like this
437918
star this property registered interest false more like this
star this property date less than 2015-12-14more like thismore than 2015-12-14
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Pharmaceutical Price Regulation Scheme more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what estimate he has made of the financial effect of companies leaving the voluntary pharmaceutical price regulation scheme in the 2015-16 financial year. more like this
star this property tabling member constituency Aberavon more like this
star this property tabling member printed
Stephen Kinnock more like this
star this property uin 19895 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-12-17more like thismore than 2015-12-17
star this property answer text <br /><p>Five companies have left the Pharmaceutical Price Regulation Scheme since January 2014 as follows:</p><br /><p>- Derma November 2014;</p><p>- Genus (Thornton &amp; Ross) November 2014;</p><p>- Vifor May 2015;</p><p>- Baxter October 2015; and</p><p>- Martindale October 2015</p><br /><p>The Department estimates the financial effect to be a loss of around £10 million in 2015/16.</p><br /><p>The Department’s consultation on options to amend the statutory scheme to control prices of branded health service medicines closed on 4 December 2015. The consultation was accompanied by an Impact Assessment which can be accessed:</p><br /><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf</a></p><br /><p>The Department’s analysis in the Impact Assessment concludes that the options would reduce National Health Service spending on drugs without affecting the use of those drugs in the NHS. The consultation sought views, comments and evidence on the potential impacts and operation of the options to revise thestatutory branded prices scheme. The Department is considering the responses received and will respond to the consultation in early 2016.</p><br />
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
19894 more like this
19897 more like this
star this property question first answered
less than 2015-12-17T16:19:37.14Zmore like thismore than 2015-12-17T16:19:37.14Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
4359
unstar this property label Biography information for Stephen Kinnock more like this
437919
star this property registered interest false more like this
star this property date less than 2015-12-14more like thismore than 2015-12-14
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading NHS: Drugs more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what assessment his Department has made of the effect on trends in the number of medicines supplied to the NHS of each of the three options set out in its recent consultation, Changes to the Statutory Scheme to Control the Prices of Branded Health Service Medicines, published on 10 September 2015; and if he will make a statement. more like this
star this property tabling member constituency Aberavon more like this
star this property tabling member printed
Stephen Kinnock more like this
star this property uin 19897 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-12-17more like thismore than 2015-12-17
star this property answer text <br /><p>Five companies have left the Pharmaceutical Price Regulation Scheme since January 2014 as follows:</p><br /><p>- Derma November 2014;</p><p>- Genus (Thornton &amp; Ross) November 2014;</p><p>- Vifor May 2015;</p><p>- Baxter October 2015; and</p><p>- Martindale October 2015</p><br /><p>The Department estimates the financial effect to be a loss of around £10 million in 2015/16.</p><br /><p>The Department’s consultation on options to amend the statutory scheme to control prices of branded health service medicines closed on 4 December 2015. The consultation was accompanied by an Impact Assessment which can be accessed:</p><br /><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/460011/Annex_C_Statutory_Scheme_2014_IA.pdf</a></p><br /><p>The Department’s analysis in the Impact Assessment concludes that the options would reduce National Health Service spending on drugs without affecting the use of those drugs in the NHS. The consultation sought views, comments and evidence on the potential impacts and operation of the options to revise thestatutory branded prices scheme. The Department is considering the responses received and will respond to the consultation in early 2016.</p><br />
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
19894 more like this
19895 more like this
star this property question first answered
less than 2015-12-17T16:19:37.19Zmore like thismore than 2015-12-17T16:19:37.19Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
4359
unstar this property label Biography information for Stephen Kinnock more like this
423864
star this property registered interest false more like this
star this property date less than 2015-10-26more like thismore than 2015-10-26
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Crohn's Disease more like this
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what progress has been made on tackling Crohn's disease. more like this
star this property tabling member constituency South Suffolk more like this
star this property tabling member printed
James Cartlidge more like this
star this property uin 13375 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-10-29more like thismore than 2015-10-29
star this property answer text <br /><p>Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.</p><br /><p>Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.</p><br /><p>In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn’s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.</p><br /><p>In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.</p><br /><p>NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn’s diseases and ulcerative colitis in its guidance <em>Crohn’s Disease Management in Adults, Children and Young People</em> in October 2012, and <em>Ulcerative Colitis</em> <em>Management in Adults, Children and Young People</em> , published in June 2013. Treatment for both Crohn’s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.</p><br />
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
13299 more like this
13300 more like this
star this property question first answered
less than 2015-10-29T17:23:06.45Zmore like thismore than 2015-10-29T17:23:06.45Z
star this property answering member
4020
star this property label Biography information for George Freeman remove filter
star this property tabling member
4519
unstar this property label Biography information for James Cartlidge more like this